C07D 409/04
Directly linked by a ring-member-to-ring-member bond
Official title: directly linked by a ring-member-to-ring-member bond
C07D409/04 (Directly linked by a ring-member-to-ring-member bond) appears on 3,649 US grants and 3,982 published applications in this corpus.
Search patents in C07D- Granted patents
- 3,649
- Published applications
- 3,982
- Assignees
- 1,468
- Inventors
- 12,208
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 20 | 0 |
| 1977 | 11 | 0 |
| 1978 | 6 | 0 |
| 1979 | 1 | 0 |
| 1980 | 3 | 0 |
| 1981 | 2 | 0 |
| 1982 | 5 | 0 |
| 1983 | 3 | 0 |
| 1984 | 8 | 0 |
| 1985 | 22 | 0 |
| 1986 | 25 | 0 |
| 1987 | 33 | 0 |
| 1988 | 38 | 0 |
| 1989 | 31 | 0 |
| 1990 | 26 | 0 |
| 1991 | 42 | 0 |
| 1992 | 49 | 0 |
| 1993 | 42 | 0 |
| 1994 | 43 | 0 |
| 1995 | 55 | 0 |
| 1996 | 68 | 0 |
| 1997 | 77 | 0 |
| 1998 | 61 | 0 |
| 1999 | 54 | 0 |
| 2000 | 73 | 0 |
| 2001 | 63 | 14 |
| 2002 | 91 | 77 |
| 2003 | 90 | 158 |
| 2004 | 63 | 193 |
| 2005 | 78 | 181 |
| 2006 | 88 | 167 |
| 2007 | 96 | 192 |
| 2008 | 102 | 157 |
| 2009 | 124 | 200 |
| 2010 | 126 | 208 |
| 2011 | 130 | 191 |
| 2012 | 158 | 170 |
| 2013 | 134 | 148 |
| 2014 | 165 | 181 |
| 2015 | 169 | 207 |
| 2016 | 127 | 166 |
| 2017 | 143 | 153 |
| 2018 | 138 | 158 |
| 2019 | 129 | 148 |
| 2020 | 114 | 149 |
| 2021 | 103 | 139 |
| 2022 | 98 | 146 |
| 2023 | 88 | 157 |
| 2024 | 76 | 122 |
| 2025 | 106 | 115 |
| 2026 | 52 | 85 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Amyloid targeting agents and methods of using the same22 Sep 2026US 12,741,949 B2Amydis, Inc.
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Compounds, compositions, and methods for modulating calcium ion homeostasis8 Sep 2026US 12,729,181 B2The Regents of the University of California
- Aryltetrahydropyridazine derivative or salt thereof, insecticidal agent containing the compound, and method of use thereof1 Sep 2026US 12,723,036 B2Nihon Nohyaku Co., Ltd.
- 5-(thiophen-2-yl)-1 H-tetrazole derivative as BCKDK inhibitors useful for treating various diseases25 Aug 2026US 12,715,863 B2Pfizer Inc.
- Therapeutic compounds24 Sep 2026US 2026/0285836 A1Rutgers, The State University of New Jersey
- Antibacterial compounds17 Sep 2026US 2026/0274816 A1The Penn State Research Foundation
- Matrix metalloproteinase (mmp) inhibitors and methods of use thereof10 Sep 2026US 2026/0265232 A1Foresee Pharmaceuticals USA, Inc.
- Novel compounds with mtorc2-inhibitory activity and uses thereof10 Sep 2026US 2026/0265267 A1Aliad Biopharma
- Err modulators3 Sep 2026US 2026/0257998 A1University of Health Sciences & Pharmacy in St. Louis
Most cited
By later US patents
- Pyrimidine derivatives and processes for the preparation thereof595US 5,521,184 ACiba-Geigy Corporation · 1996
- Cyclic-substituted unsymmetrical cyanine dyes371US 5,436,134 AMolecular Probes, Inc. · 1995
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation222US 5,616,601 AG. D. Searle & Co. · 1997
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995